Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS

Kate I. Stevens; Eleni Frangou; Jae Il Shin; Hans Joachim Anders; Annette Bruchfeld; Ulf Schönermarck; Thomas Hauser; Kerstin Westman; Gema M. Fernandez-Juarez; Jürgen Floege; Dimitrios Goumenos; Kultigin Turkmen; Cees van Kooten; Stephen P. McAdoo; Vladimir Tesar; Mårten Segelmark; Duvuru Geetha; David R.W. Jayne; Andreas Kronbichler

doi:10.1093/ndt/gfac052

Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS

Kate I. Stevens, Eleni Frangou, Jae Il Shin, Hans Joachim Anders, Annette Bruchfeld, Ulf Schönermarck, Thomas Hauser, Kerstin Westman, Gema M. Fernandez-Juarez, Jürgen Floege, Dimitrios Goumenos, Kultigin Turkmen, Cees van Kooten, Stephen P. McAdoo, Vladimir Tesar, Mårten Segelmark, Duvuru Geetha, David R.W. Jayne, Andreas Kronbichler

Department of Pediatrics

Research output: Contribution to journal › Review article › peer-review

24 Citations (Scopus)

Abstract

Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.

Original language	English
Pages (from-to)	1400-1410
Number of pages	11
Journal	Nephrology Dialysis Transplantation
Volume	37
Issue number	8
DOIs	https://doi.org/10.1093/ndt/gfac052
Publication status	Published - 2022

Bibliographical note

Publisher Copyright:
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA. All rights reserved.

All Science Journal Classification (ASJC) codes

Nephrology
Transplantation

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/ndt/gfac052

Cite this

Stevens, K. I., Frangou, E., Shin, J. I., Anders, H. J., Bruchfeld, A., Schönermarck, U., Hauser, T., Westman, K., Fernandez-Juarez, G. M., Floege, J., Goumenos, D., Turkmen, K., van Kooten, C., McAdoo, S. P., Tesar, V., Segelmark, M., Geetha, D., Jayne, D. R. W., & Kronbichler, A. (2022). Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS. Nephrology Dialysis Transplantation, 37(8), 1400-1410. https://doi.org/10.1093/ndt/gfac052

@article{ee32303d84294b52a1140b35094fe189,

title = "Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS",

abstract = "Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.",

keywords = "IgA nephropathy, immunology, immunosuppression, rituximab, vasculitis",

author = "Stevens, {Kate I.} and Eleni Frangou and Shin, {Jae Il} and Anders, {Hans Joachim} and Annette Bruchfeld and Ulf Sch{\"o}nermarck and Thomas Hauser and Kerstin Westman and Fernandez-Juarez, {Gema M.} and J{\"u}rgen Floege and Dimitrios Goumenos and Kultigin Turkmen and {van Kooten}, Cees and McAdoo, {Stephen P.} and Vladimir Tesar and M{\aa}rten Segelmark and Duvuru Geetha and Jayne, {David R.W.} and Andreas Kronbichler",

year = "2022",

doi = "10.1093/ndt/gfac052",

language = "English",

volume = "37",

pages = "1400--1410",

journal = "Nephrology Dialysis Transplantation",

issn = "0931-0509",

publisher = "Oxford University Press",

number = "8",

}

Stevens, KI, Frangou, E, Shin, JI, Anders, HJ, Bruchfeld, A, Schönermarck, U, Hauser, T, Westman, K, Fernandez-Juarez, GM, Floege, J, Goumenos, D, Turkmen, K, van Kooten, C, McAdoo, SP, Tesar, V, Segelmark, M, Geetha, D, Jayne, DRW & Kronbichler, A 2022, 'Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS', Nephrology Dialysis Transplantation, vol. 37, no. 8, pp. 1400-1410. https://doi.org/10.1093/ndt/gfac052

TY - JOUR

T1 - Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases

T2 - consensus statements from the ERA-IWG and EUVAS

AU - Stevens, Kate I.

AU - Frangou, Eleni

AU - Shin, Jae Il

AU - Anders, Hans Joachim

AU - Bruchfeld, Annette

AU - Schönermarck, Ulf

AU - Hauser, Thomas

AU - Westman, Kerstin

AU - Fernandez-Juarez, Gema M.

AU - Floege, Jürgen

AU - Goumenos, Dimitrios

AU - Turkmen, Kultigin

AU - van Kooten, Cees

AU - McAdoo, Stephen P.

AU - Tesar, Vladimir

AU - Segelmark, Mårten

AU - Geetha, Duvuru

AU - Jayne, David R.W.

AU - Kronbichler, Andreas

PY - 2022

Y1 - 2022

N2 - Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.

AB - Patients with immune-mediated kidney diseases are at increased risk of severe coronavirus disease 2019 (COVID-19). The international rollout of COVID-19 vaccines has provided varying degrees of protection and enabled the understanding of vaccine efficacy and safety. The immune response to COVID-19 vaccines is lower in most patients with immune-mediated kidney diseases; either related to immunosuppression or low risk of de novo or relapsing immune-mediated kidney disease. Population-based studies will determine whether this is causal or coincidental. Such cases respond to standard management, including the use of immunosuppression. The Immunonephrology Working Group and European Vasculitis Society recommend that patients with immune-mediated kidney diseases follow national guidance on vaccination. Booster doses based on antibody measurements could be considered.

KW - IgA nephropathy

KW - immunology

KW - immunosuppression

KW - rituximab

KW - vasculitis

UR - http://www.scopus.com/inward/record.url?scp=85131505857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131505857&partnerID=8YFLogxK

U2 - 10.1093/ndt/gfac052

DO - 10.1093/ndt/gfac052

M3 - Review article

C2 - 35244174

AN - SCOPUS:85131505857

SN - 0931-0509

VL - 37

SP - 1400

EP - 1410

JO - Nephrology Dialysis Transplantation

JF - Nephrology Dialysis Transplantation

IS - 8

ER -

Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases: consensus statements from the ERA-IWG and EUVAS

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this